Jonathan Volpatti

Jonathan joined BioSymetrics in March 2022, with a background in molecular genetics (MSc) and biology (BHSc). As a graduate student, he performed phenotypic drug screens to identify lead compounds for treatment of rare neuromuscular disorders. At BioSymetrics, Jonathan’s focus is on drug discovery, validating machine learning predictions through experimentation, and innovating methods to increase drug screening throughput.